U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT07521371) titled 'Intranasal Insulin for Autism Spectrum Disorder in Children and Young Adults Aged 4 to 21 Years' on April 01.
Brief Summary: This observational study evaluates the real-world use of intranasal insulin in children and young adults with autism spectrum disorder (ASD) utilizing the ViaNase™ device developed by Kurve Therapeutics. Intranasal insulin represents an off label use of an FDA approved medication and is prescribed by participants' treating healthcare providers as part of routine clinical care.
Insulin is a hormone involved in cerebral energy metabolism and may play a role in cognitive processes such as learning, memory...